Three drugs — Vioxx, Ketek and Avandia — are casting long shadows over the congressional debate on how to update and revise the 15-year-old system that has dramatically sped up the process of bringing prescription medicines to American consumers…. As Congress debates reauthorizing the user-fee law, it is considering several proposals that would raise the fees and devote a larger portion of them to 'post-market surveillance' of drugs — the regulatory equivalent of chasing the horses after they are out of the barn. (Washington Post, Thursday)
Have they considered the free market?
FEE Timely Classic
A World Without the FDA by Russell Roberts